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Summary
The sterol regulatory element binding protein (SREBP) family of transcription factors controls cholesterol and lipid metab-
olism. The nuclear forms of these proteins are rapidly degraded by the ubiquitin-proteasome pathway, but the signals and
factors required for this are unknown. Here, we identify a phosphodegron in SREBP1a that serves as a recognition motif
for the SCFFbw7 ubiquitin ligase. Fbw7 interacts with nuclear SREBP1a and enhances its ubiquitination and degradation
in a manner dependent on the phosphorylation of T426 and S430 by GSK-3. Fbw7 also degrades nuclear SREBP1c and
SREBP2, and inactivation of endogenous Fbw7 results in stabilization of nuclear SREBP1 and -2, enhanced expression of
SREBP target genes, enhanced synthesis of cholesterol and fatty acids, and enhanced receptor-mediated uptake of LDL.
Thus, our results suggest that Fbw7 may be a major regulator of lipid metabolism through control of the phosphorylation-
dependent degradation of the SREBP family of transcription factors.Introduction
Members of the sterol regulatory element binding protein
(SREBP) family of transcription factors control cholesterol and
lipid metabolism and play critical roles during adipocyte differ-
entiation (Brown and Goldstein, 1999; Osborne, 2000). In addi-
tion, SREBP1c is an important regulator of insulin-dependent
gene expression (Foretz et al., 1999; Shimomura et al., 1998).
Two genes, srebf1 and srebf2, encode three different SREBP
proteins, SREBP1a, SREBP1c, and SREBP2 (Edwards et al.,
2000; Osborne, 2000). SREBPs are synthesized as large pre-
cursor proteins that are inserted into the nuclear and endoplas-
mic reticulum membranes and are transcriptionally inactive. In
sterol-depleted cells, SREBP cleavage-activating protein
(SCAP) escorts SREBP to the Golgi apparatus where SREBP
is processed sequentially by two membrane-associated prote-
ases that release the NH2-terminal domain (Rawson et al.,
1997; Sakai et al., 1998). This transcriptionally active fragment
of SREBP is translocated to the nucleus and binds to the pro-
moters of SREBP target genes. Most of these genes are in-
volved in the control of lipid biosynthesis and metabolism. In
sterol-loaded cells, the SCAP/SREBP complex is trapped in
the ER as a result of sterol-induced binding of SCAP to Insigs,
which are resident proteins of the ER membrane (Yang et al.,
2002). Therefore, the cleavage of SREBP is prevented and
transcription of the lipid biosynthetic target genes declines.
Many transcription factors, particularly those involved in the
control of cell growth, are unstable proteins targeted for degra-
dation by the ubiquitin-proteasome system (Conaway et al.,
2002; Muratani and Tansey, 2003). The nuclear, transcription-CELL METABOLISM : JUNE 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEVally active fragments of SREBPs are unstable and degraded by
the proteasome system in a ubiquitination-dependent manner
(Hirano et al., 2001). We have previously demonstrated that the
ubiquitination and degradation of SREBPs can be regulated by
coactivator-mediated acetylation (Giandomenico et al., 2003).
In addition, it has been suggested that nuclear SREBPs are, at
least in part, ubiquitinated and degraded as a functional conse-
quence of their transcriptional activity (Sundqvist and Ericsson,
2003). The factors regulating the ubiquitination and degrada-
tion of SREBPs have, however, not been identified.
Polyubiquitination is the rate-limiting step in protein degra-
dation and involves a three-step cascade of ubiquitin-transfer
reactions (Glickman and Ciechanover, 2002). First, the ubiqui-
tin-activating enzyme (E1) activates ubiquitin and transfers it to
the ubiquitin-conjugating enzyme (E2). The E2 acts together
with a specificity-determining component, E3, to transfer ubiqui-
tin to the target protein. E3s are adaptors that link the ubiquiti-
nation machinery of the E2 to specific substrates. The largest
and most versatile class of E3s is the Skp1-Cul1-F box protein
ubiquitin ligases (SCFs). SCFs are modular complexes that con-
sist in mammalian cells of Skp1, Cul1, Rbx1, and one of a fam-
ily of F box proteins (Cardozo and Pagano, 2004; Jin et al.,
2004). Distinct regions of the F box protein confer the ability to
bind substrates, whereas the F box motif docks with Skp1,
which in turn binds to the Cullin scaffold. Many F box proteins
recognize and bind phosphorylated Ser and Thr residues in
substrate proteins. In Fbw7 (also known as hCdc4), WD40 re-
peats mediate recognition of phosphorylated substrates, and
Fbw7 targets phosphorylated cyclin E, c-Myc, and c-Jun for
proteolysis (Koepp et al., 2001; Nateri et al., 2004; Strohmaier
et al., 2001; Welcker et al., 2004; Yada et al., 2004). Fbw7 isIER INC. DOI 10.1016/j.cmet.2005.04.010 379
A R T I C L Emutated in breast, endometrial, ovarian, and colon cancer and
functions as a tumor suppressor whose loss causes genetic
instability (Ekholm-Reed et al., 2004; Rajagopalan et al., 2004;
Spruck et al., 2002; Strohmaier et al., 2001). Deletion of Fbw7
in the mouse causes embryonic lethality with defects in cardio-
vascular development and increased cyclin E and Notch pro-
tein in the embryo and placenta (Tetzlaff et al., 2004; Tsune-
matsu et al., 2004). In the current study, we identify two
residues, T426 and S430, in SREBP1a that are phosphorylated
in the nuclear form of the protein. Mutation of either of these
residues greatly stabilizes nuclear SREBP1a. The sequence
surrounding T426 and S430 conforms to the phospho binding
motif for Fbw7, termed the Cdc4 phosphodegron, or CPD,
found in cyclin E and c-Myc. We show that Fbw7 interacts with
nuclear SREBP1a and regulates its ubiquitination and degrada-
tion in a manner dependent on the phosphorylation of T426
and S430. Consequently, expression of Fbw7 inhibits SREBP-
dependent transcription, and this effect is dependent on T426
and S430. Fbw7 also degrades nuclear SREBP1c and SREBP2,
suggesting that Fbw7 controls the stability of all members of
the SREBP family of transcription factors. Furthermore, inacti-
vation of endogenous Fbw7 results in stabilization of nuclear
SREBP1 and -2, enhanced expression of endogenous SREBP
target genes, enhanced synthesis of cholesterol and fatty
acids, and enhanced uptake of LDL. Thus, our results indicate
that Fbw7 is a major regulator of lipid metabolism by con-
trolling the phosphorylation-dependent ubiquitination and deg-
radation of the SREBP family of transcription factors.
Results
SCFFbw7 negatively regulates the stability
and function of SREBP
Many proteins regulated by ubiquitin-mediated degradation are
recognized by E3 ligases of the multisubunit RING finger type.
Most of these complexes contain a Cullin (Cul) protein, which
functions as a molecular scaffold and interacts with both the
adaptor subunit and the RING finger protein. Importantly, dif-
ferent adaptor proteins interact with specific Cul proteins.
Since Cullins recruit specific families of E3 ligases, dominant-
negative (DN) Cullins can be used to identify which family of
ligases that interact with a specific substrate. If the expression
of a specific DN Cullin increases the steady-state abundance
of a cotransfected protein, this indicates that the E3 belongs
to the family of ligases that interact with that specific Cullin. To
identify the E3 complex that regulates the stability of nuclear
SREBP1a, Myc-SREBP1a was expressed in 293T cells, either
alone or together with DN Cul1-5. As illustrated in Figure 1A,
the levels of SREBP1a were low in the transfected 293T cells
and specifically enhanced in cells expressing DN-Cul1 (com-
pare lanes 1 and 2 in Figure 1A), indicating that the degradation
of SREBP1a is regulated by a SCF complex. Similarly, we
found that SREBP1a was specifically stabilized in cells ex-
pressing DN-Ubc3/hCdc34 (Figure S1), an E2 ligase often as-
sociated with SCF complexes. To analyze if SCF complexes
regulated the function of endogenous SREBP, U2OS cells were
transfected with a SREBP-responsive promoter reporter gene
in the absence or presence of DN Cul1-5 (Figure 1B). As a
result of sterol-regulated processing of endogenous SREBP,
transcription from the promoter reporter gene was low in cells
incubated in the presence of sterols and induced in cells incu-380bated in the absence of sterols. Importantly, expression of DN-
Cul1 enhanced transcription from the promoter reporter gene,
indicating that endogenous SREBPs are regulated by a Cul1-
containing SCF complex.
There are two main families of F box proteins: the Fbw family,
containing WD40 repeats, and the Fbl family, containing leu-
cine-rich repeats. To test if the stability of SREBP1a was regu-
lated by any of these proteins, nuclear SREBP1a was ex-
pressed in 293T cells, either alone or in the presence of
individual members of these families of F box proteins. As il-
lustrated in Figure 1C, coexpression of the F box protein Fbw7
decreased the levels of SREBP1a. In contrast, the other F box
proteins did not decrease the expression of SREBP1a, and
some even increased the expression of SREBP1a. Fbw7 also
induced the degradation of nuclear SREBP1c and SREBP2
(Figure S1), suggesting that Fbw7 regulates the stability of all
members of the SREBP family of proteins. Expression of an
Fbw7 protein containing a mutation in its F box or expression
of the WD40 domain alone did not induce the degradation of
SREBP1a, indicating that both domains are important for
Fbw7-mediated degradation (Figure 1D). Rather, the nonfunc-
tional Fbw7 proteins worked in a DN manner, stabilizing
SREBP1a (compare lanes 1, 3, and 4 in Figure 1D). The Fbw7-
mediated degradation of SREBP1a was inhibited by the pro-
teasome inhibitor MG-132 (Figure 1E), indicating that the pro-
cess is dependent on the ubiquitin-proteasome system. There
are three different isoforms of Fbw7: α, β, and γ. Both the α and
γ isoforms are localized in the nucleus, whereas the β isoform is
cytoplasmic. To determine if the different isoforms of Fbw7
have different specificity for SREBP, 293T cells were trans-
fected with nuclear SREBP1a either alone or in the presence
of increasing amounts of the individual isoforms of Fbw7. The
α and γ isoforms of Fbw7 greatly enhanced the degradation of
SREBP1a, while coexpression of the β isoform had a signifi-
cantly lower effect, if any, on the turnover of SREBP1 (Figure
1F). Expression of Fbw7α and -γ inhibited the expression of a
SREBP-dependent promoter reporter gene, whereas Fbw7β
and the nonfunctional mutants of Fbw7α were unable to do so
(Figure 1G), supporting the hypothesis that Fbw7α and -γ regu-
late the stability and function of endogenous SREBPs. To-
gether, these results demonstrate that the F box protein Fbw7
regulates the turnover and function of nuclear SREBP1a, -1c,
and -2.
Fbw7-mediated degradation of SREBP1a
is dependent on T426 and S430
The sequence surrounding T426 and S430 in SREBP1a con-
forms to the CPD found in cyclin E and c-Myc (Figure 2A),
suggesting that this region of SREBP1a contains an Fbw7
binding motif. Mutation of T426, S430, or both residues to ala-
nine in the nuclear form of SREBP1a drastically enhanced the
steady-state levels of the protein when expressed in 293T cells
(Figure 2B), suggesting that both T426 and S430 are required
for efficient degradation of nuclear SREBP1a. This hypothesis
was supported by our observation that mutation of T426 and
S430, either individually or in combination, blocked Fbw7-
mediated degradation of SREBP1a (Figure 2C). To confirm that
the reduced abundance of SREBP1a in response to Fbw7 ex-
pression resulted from increased proteolysis, we measured the
half-life of nuclear SREBP1a, either wild-type or the T426A/
S430A mutant, in the absence or presence of coexpressedCELL METABOLISM : JUNE 2005
Phosphorylation-dependent ubiquitination of SREBPFigure 1. SCFFbw7 negatively regulates the stability and function of SREBP1a
A) 293T cells were transfected with a vector expressing Myc-tagged nuclear (N) SREBP1a in the absence or presence of the indicated Flag-tagged DN-Cullins. The
levels of SREBP1a, DN-Cullins, and α-tubulin in cell lysates were determined by Western blotting.
B) U2OS cells were transfected with SYNSRE-luc in the absence or presence of the indicated DN-Cullins, and the cells were grown in the absence or presence of
sterols. Thirty-six hours after transfection, the luciferase activity was measured.
C) 293T cells were transfected with Myc-SREBP1a in the absence or presence of the indicated GST-tagged F box proteins. The levels of SREBP1a, F box proteins,
and α-tubulin in cell lysates were detected by Western blotting.
D) 293T cells were transfected with Myc-SREBP1a in the absence or presence of Flag-Fbw7α, either wild-type or the indicated mutants. The levels of SREBP1a,
Fbw7α, and α-tubulin in cell lysates were detected by Western blotting.
E) 293T cells were transfected with Myc-SREBP1a in the absence or presence of GST-Fbw7α and treated with vehicle alone (DMSO) or MG-132 (50 M) for 6 hr prior
to lysis. The levels of SREBP1a, Fbw7α, and α-tubulin in cell lysates were detected by Western blotting.
F) 293T cells were transfected with Myc-SREBP1a in the absence or presence of increasing amounts of GST-tagged Fbw7α, -β, or -γ. The levels of SREBP1a, Fbw7,
and α-tubulin in cell lysates were detected by Western blotting.
G) 293T cells were transfected with SYNSRE-luc in the absence or presence of Fbw7α, -β, and -γ or the indicated mutants of Fbw7α, and the cells were grown in the
absence or presence of sterols. Thirty-six hours after transfection, the luciferase activity was measured.Fbw7. Expression of Fbw7 enhanced the turnover of wild-type
SREBP1a, whereas the T426A/S430A mutant was stable and
insensitive to Fbw7 expression (Figure 2D). The transcriptional
activities of the T426A, S430A, and T426A/S430A mutants
were enhanced compared to the wild-type protein and were
insensitive to Fbw7 expression (Figure 2E), further supporting
the role of T426 and S430 in regulating the stability and func-
tion of SREBP1a. Our data predict that Fbw7 functions to re-
cruit the SCF complex to nuclear SREBP1 and promote its
ubiquitination. To test this idea, we determined whether Fbw7
could induce the ubiquitination of nuclear SREBP1a when the
two proteins were expressed in 293T cells. As illustrated in Fig-
ure 2F, expression of Fbw7α stimulated the ubiquitination of
wild-type SREBP1a, whereas it was unable to enhance the
ubiquitination of the T426A/S430A mutant.
SREBPs interact with Fbw7 in a phosphorylation-
dependent manner
To determine whether Fbw7 and SREBP1a associate in vivo,
we immunoprecipitated Fbw7 from cells expressing nuclear
SREBP1a and Fbw7. The cells were also transfected with DN-CELL METABOLISM : JUNE 2005Cul1 to prevent Fbw7-dependent degradation of SREBP1a.
Wild-type SREBP1a and Fbw7α interacted efficiently, whereas
mutation of T426 or S430 in SREBP1a blocked its interaction
with Fbw7α (Figure 3A). Fbw7α also interacted with SREBP1c
and SREBP2 (Figure S2). T426 and S430 correspond to S432
and S436 in SREBP2 (Figure 2A). Interestingly, the interaction
between SREBP2 and Fbw7, as well as Fbw7-mediated degra-
dation of SREBP2, was lost when S432 or S436 were mutated
(Figure S2). The interactions between Fbw7 and c-Myc and
cyclin E are dependent on phosphorylation of conserved Thr
and Ser residues in the CPD motifs of these proteins. To deter-
mine if T426 or S430 in SREBP1a was phosphorylated in vivo,
we generated phosphorylation-specific antibodies directed
against these residues. When expressed in 293T cells, nuclear
SREBP1a was recognized by both antibodies in a phosphory-
lation-dependent manner (Figure S3), indicating that both resi-
dues are phosphorylated in vivo. When the antibodies were
used to analyze the phosphorylation of endogenous SREBP1,
we found that nuclear SREBP1 phosphorylated on T426 and
S430 accumulated in HeLa, HepG2, and U2OS cells treated
with the proteasome inhibitor MG-132 (Figure 3B and data not381
A R T I C L EFigure 2. Fbw7-mediated degradation of SREBP1a is dependent on T426 and S430
A) Sequence alignment of the Cdc4 phosphodegron (CPD) in SREBP1a, SREBP2, c-Myc, and cyclin E.
B) 293T cells were transfected with Myc-SREBP1a, either wild-type or the indicated point mutants. The levels of SREBP1a and α-tubulin in cell lysates were determined
by Western blotting.
C) 293T cells were transfected with Myc-SREBP1a, either wild-type or the indicated point mutants, in the absence or presence of Flag-Fbw7α. The levels of SREBP1a,
Fbw7α, and α-tubulin in cell lysates were determined by Western blotting.
D) 293T cells were transfected with Myc-SREBP1a, either wild-type or the T426A/S430A mutant, in the absence or presence of Flag-Fbw7α. Thirty-six hours after
transfection, the cells were either lysed directly or incubated in the presence of cyclohexamide (100 g/ml) for the indicated time period in order to determine SREBP
turnover. The levels of SREBP1a were determined by Western blotting.
E) 293T cells were transfected with SYNSRE-luc in the absence or presence of SREBP1a, either wild-type or the indicated point mutants, in the absence or presence
of Fbw7α. Thirty-six hours after transfection, the luciferase activity was measured.
F) 293T cells were transfected with Flag-SREBP1a, either wild-type or the T426A/S430A mutant, and HA-ubiquitin in the absence or presence of GST-Fbw7α. SREBP1a
was immunoprecipitated (IP) from whole-cell lysates with anti-Flag antibodies and separated by SDS-PAGE. Ubiquitination of SREBP1a and the amount of SREBP1a
in the immunoprecipitates, and the levels of SREBP1a and Fbw7α in whole-cell lysates (WCL), were determined by Western blotting.shown), indicating that nuclear SREBP1 phosphorylated on
these residues is rapidly turned over by proteasome-mediated
degradation. We detected no phosphorylation of T426 or S430
in the membrane-associated precursor form of SREBP1. This
result is in agreement with our observation that Fbw7 is unable
to enhance the degradation of the precursor form of SREBP1a
(data not shown). Thus, our data indicate that nuclear SREBP1
is phosphorylated on T426 and S430, suggesting that the
phosphorylation of these residues is important for Fbw7 bind-
ing and Fbw7-dependent degradation of SREBP1. To further
define the role of T426 and S430 phosphorylation in mediating
Fbw7 binding, we used synthetic peptides corresponding to
the CPD motif in SREBP1a in peptide pull-down assays with
Fbw7α. The binding of Fbw7α to the CPD peptide was strongly
dependent upon T426 phosphorylation (Figure 3C). Interest-
ingly, phosphorylation of S430 was not required for Fbw7 bind-
ing in vitro, although Fbw7 bound to the doubly phosphory-
lated peptide more avidly (compare lanes 3 and 5 in Figure3823C). In contrast, mutation of S430 blocked both the interaction
between SREBP1a and Fbw7 and Fbw7-mediated degradation
of SREBP1a in vivo (Figures 3A and 2C). Similar results have
also been reported for the CPD in c-Myc; phosphorylation of
T58 is required for interaction with Fbw7, whereas both T58
and S62 are required for Fbw7-mediated turnover of c-Myc
(Welcker et al., 2004; Yada et al., 2004). In c-Myc, T58 phos-
phorylation requires S62 phosphorylation, and it will be inter-
esting to analyze if the phosphorylation of T426 and S430 in
SREBP1a is regulated in a similar manner. Similar results to
those shown in Figure 3C were also obtained when peptides
corresponding to the CPD motif in SREBP2 were used in pep-
tide pull-down assays with Fbw7α (Figure S4), indicating that
phosphorylation of S432 and S436 in SREBP2 is critical for its
interaction with Fbw7. Taken together, our data indicate that
phosphorylation of the CPD motifs in SREBP1 and SREBP2
regulates their interactions with Fbw7 and suggest that phos-CELL METABOLISM : JUNE 2005
Phosphorylation-dependent ubiquitination of SREBPFigure 3. SREBP1a and Fbw7 interact in a phosphorylation-dependent manner
A) 293T cells were transfected with DN-Cul1 and Myc-SREBP1a, either wild-type
or the indicated point mutants, in the absence or presence of Flag-Fbw7α. Cell
lysates were immunoprecipitated with anti-Flag antibodies. Immunoprecipitated
SREBP1a and Fbw7α and the levels of SREBP1a in cell lysates were determined
by Western blotting.
B) HeLa cells were treated with vehicle alone (DMSO) or MG-132 (50 M) for 4
hr. The levels of SREBP1 and α-tubulin and the phosphorylation of SREBP1 on
T426 (pT426) and S430 (pS430) were determined by Western blotting.CELL METABOLISM : JUNE 2005ing in the accumulation of nuclear SREBP1. We did not ob-
C) Flag-Fbw7α was expressed in 293T cells, and the cell lysates were used in
peptide pull-down assays, using four separate peptides corresponding to resi-
dues 422–433 of human SREBP1a, either unphosphorylated (Ref) or the same
peptide phosphorylated on T426 (pT426), S430 (pS430), or both residues (pT426/
pS430). The bound proteins were subjected to SDS/PAGE and Western blotting
using 20% of input as control.phorylation is required for Fbw7-driven turnover of the nuclear
forms of both proteins.
GSK-3 phosphorylates the CPD motif in SREBP1
There is substantial evidence that GSK-3β regulates c-Myc
stability and is the primary c-Myc T58 kinase. In addition, the
CPD in cyclin E is also phosphorylated by GSK-3β. Recombi-
nant GSK-3β phosphorylated both T426 and S430 in recombi-
nant SREBP1a (Figure S5), indicating that GSK-3β could regu-
late the function of the CPD motif in SREBP1a. To test this
hypothesis, recombinant SREBP1a, either wild-type or the
T426A/S430A mutant, was incubated with recombinant GSK-
3β, and the interaction between the phosphorylated SREBP
proteins and Fbw7α were tested. As illustrated in Figure 4A,
GSK3-mediated phosphorylation of wild-type SREBP1a in-
duced a 4-fold increase in its interaction with Fbw7α (compare
lanes 1 and 2), whereas the interaction between Fbw7α and
the T426A/S430A mutant was unaffected (compare lanes 3
and 4), indicating that phosphorylation of T426 and S430 in
SREBP1a is critical for its interaction with Fbw7. To test
whether endogenous GSK-3 could phosphorylate the CPD
motif in endogenous SREBP1, HeLa cells were treated with
lithium, a pharmacologic GSK-3 inhibitor. Inhibition of GSK-3
reduced the phosphorylation of both T426 and S430 (Figure 4B),
indicating that both residues are phosphorylated by GSK-3 in
vivo. This hypothesis was supported by our observation that
the phosphorylation of T426 and S430 was reduced when
nuclear SREBP1a was cotransfected with a peptide corre-
sponding to the axin GSK-3-interaction domain (GID) that
binds to and inhibits GSK-3 (Figure 4C). In contrast, a control
GID peptide bearing a point mutation that prevents GSK-3 in-
teraction did not affect the phosphorylation of SREBP1a. Fur-
thermore, siRNA-mediated inactivation of GSK-3β in HeLa and
U2OS cells reduced the phosphorylation of T426 and S430 in
endogenous SREBP1 (Figure 4D), confirming that GSK-3β
targets the CPD motif in SREBP1. Importantly, inhibition of
GSK-3 by either lithium treatment or expression of the wild-
type GID prevented Fbw7-driven SREBP1a elimination in 293
cells (Figure 4E). Growth factors, including insulin and PDGF,
negatively regulate the kinase activity of GSK-3 through Akt-
mediated phosphorylation of Ser-9 in GSK-3. Both insulin and
PDGF have been reported to enhance the levels of nuclear
SREBP1 (Demoulin et al., 2004; Hegarty et al., 2005), and insu-
lin signaling is a major regulator of lipid metabolism. Thus, we
speculated that insulin-dependent inhibition of GSK-3 could
attenuate the phosphorylation of T426 and/or S430 in SREBP1
and thereby block its Fbw7-mediated degradation. As il-
lustrated in Figure 4F, a short treatment of HepG2 cells with
insulin enhanced the inhibitory phosphorylation of GSK-3.
Consequently, the phosphorylation of SREBP1 on both T426
and S430 was reduced in response to insulin treatment, result-383
A R T I C L EFigure 4. GSK-3 phosphorylates the CPD motif in SREBP1
A) 6xHis-SREBP1a, either wild-type or the T426A/S430A mutant, was incubated in the absence or presence of recombinant GSK-3β. The phosphorylated proteins
were used for pull-down assays with in vitro translated [35S]Fbw7α. No SREBP protein was added to lane 5. Following immunoprecipitation of SREBP1a and extensive
washing, the bound proteins were subjected to SDS-PAGE, and the amount of [35S]Fbw7α was determined by phosphoimage analysis. The amount of immunoprecipi-
tated 6xHis-SREBP1a was determined by Western blotting.
B) HeLa cells were treated with NaCl or LiCl for 4 hr. The expression of SREBP1, GSK-3β, and α-tubulin and the phosphorylation of SREBP1 on T426 (pT426) and
S430 (pS430) were determined by Western blotting.
C) 293 cells were transfected with Flag-SREBP1a in the presence of the axin GSK-interacting domain (GID) or an inactive GID mutant (GID*). The expression of
SREBP1, GSK-3β, and α-tubulin and the phosphorylation of SREBP1 on T426 (p426) and S430 (pS430) were determined by Western blotting.
D) U2OS (left) and HeLa (right) cells were transfected with control or GSK-3β siRNA (20 nM) for 48 hr. The expression of SREBP1, GSK-3β, and α-tubulin and the
phosphorylation of SREBP1 on T426 (pT426) and S430 (pS430) were determined by Western blotting.
E) 293 cells were transfected with Flag-SREBP1a in the absence or presence of GST-Fbw7α. In the right panel, cells were treated with either NaCl or LiCl (25 mM) 6
hr prior to lysis to inhibit endogenous GSK-3. In the left panel, cells were cotransfected with the axin GSK-interacting domain (GID) or an inactive GID mutant (GID*).
The expression of SREBP1, GSK-3β, Fbw7α, and α-tubulin in cell lysates was determined by Western blotting.
F) HepG2 cells were placed in media containing 0.5% FBS for 18 hr and either left untreated (lane 1) or treated with 100 nM insulin (lane 2) for 1 hr. The expression of
nuclear SREBP1, GSK-3β, and α-tubulin and the phosphorylation of SREBP1 on T426 (pT426) and S430 (pS430) and of GSK-3β on S9 (pGSK-3) were determined by
Western blotting.serve any induction of SREBP1a or SREBP1c mRNA in re-
sponse to the short insulin treatment (data not shown). Thus,
our results suggest that inactivation of GSK-3 in response to
insulin signaling attenuates the phosphorylation of the CPD
motif in mature SREBP1, thereby inhibiting Fbw7-mediated
degradation. Taken together, our data indicate that Fbw7-
driven SREBP1 turnover requires endogenous GSK-3 activity
and support a model in which Fbw7-dependent degradation of384SREBP1 requires phosphorylation of SREBP1 on T426 and
S430 by GSK-3.
Regulation of endogenous SREBP by endogenous Fbw7
In order to determine if endogenous Fbw7 regulates the degra-
dation of endogenous SREBP, we used siRNA targeting the
common region of Fbw7. Because antibodies that recognize
endogenous Fbw7 are not available, we confirmed the efficacyCELL METABOLISM : JUNE 2005
Phosphorylation-dependent ubiquitination of SREBPof the Fbw7 siRNA by demonstrating that the siRNA decreased
expression of transfected Flag-tagged Fbw7, using Western
blotting, and of endogenous Fbw7 mRNA, using semiquantita-
tive PCR (Figure S6). The levels of nuclear SREBP1 were en-
hanced in U2OS cells treated with the Fbw7 siRNA, whereas
no effect was observed on the precursor form of the protein
(Figure 5A). In agreement with our hypothesis, the SREBP1
protein that accumulated in response to inactivation of Fbw7
was phosphorylated on T426 and S430. Nuclear SREBP2 also
accumulated in cells treated with Fbw7 siRNA (Figure 5A), sug-
gesting that Fbw7 regulates the stability of all SREBP proteins.
To confirm that the increased levels of nuclear SREBP1 re-
sulted from decreased proteolysis, we measured the half-life of
SREBP1 in U2OS cells treated with control or Fbw7-directedFigure 5. Regulation of endogenous SREBP by endogenous Fbw7
A) U2OS cells were transfected with control or Fbw7 siRNA (20 nM) for 48 hr. The expression of SREBP1 and SREBP2 and the phosphorylation of SREBP1 on T426
(pT426) and S430 (pS430) were determined by Western blotting. The migration of the precursor (FL) and nuclear (N) forms of SREBP1 is indicated.
B) U2OS cells were transfected with control or Fbw7 siRNA (20 nM). Forty-eight hours after transfection, cells were treated with cycloheximide for the indicated times.
The levels of SREBP1 in cell lysates were detected by Western blotting. The relative amount of nuclear SREBP1 at each time point is plotted as percent of the amount
at the start of the assay (right panel).
C) 293 cells were transfected with Flag-SREBP1a (left) or Flag-SREBP2 (right), either wild-type (0.5 g) or the indicated mutant (0.05 g), together with control or
Fbw7-directed siRNA. The levels of SREBP1a, SREBP2, and α-tubulin in cell lysates were detected by Western blotting.
D) U2OS cells were transfected with the indicated promoter reporter constructs in the presence of either control or Fbw7 siRNA, and the cells were grown in the
absence or presence of sterols. Thirty-six hours after transfection, the luciferase activity was measured.
E) U2OS cells were transfected with either control or Fbw7 siRNA. Thirty-six hours after transfection, cells were placed in fresh media supplemented with [14C]acetate.
Fatty acids (upper) and cholesterol (lower) were extracted and resolved by thin-layer chromatography. Radioactive products were visualized by phosphoimage analysis.CELL METABOLISM : JUNE 2005siRNA. As illustrated in Figure 5B, nuclear SREBP1 was rapidly
degraded in control cells, whereas siRNA-mediated inactiva-
tion of Fbw7 delayed the turnover of SREBP1. Our data sug-
gest that the stabilization of SREBP1 in response to inactiva-
tion of Fbw7 should be dependent on T426 and S430. To test
this hypothesis, 293 cells expressing nuclear SREBP1a, either
wild-type or the T426A/S430A mutant, were treated with either
control or Fbw7 siRNA. Inactivation of Fbw7 enhanced the ex-
pression of wild-type SREBP1a, whereas the expression of the
T426A/S430A mutant was unaffected (Figure 5C, left), provid-
ing further support for a role of T426 and S430 in regulating
Fbw7-mediated ubiquitination and degradation of SREBP1.
Similar results were obtained when the experiment was re-
peated with wild-type SREBP2 and the S432A/S436A mutant385
A R T I C L E(Figure 5C, right). Inactivation of Fbw7 in U2OS cells enhanced
the expression of SREBP-dependent promoter reporter genes
(Figure 5D), supporting the hypothesis that Fbw7-mediated
degradation of nuclear SREBPs affects the function of these
proteins in vivo. Importantly, the effect of the Fbw7 siRNA was
dependent on SREBP, since mutation of the SREBP binding
site in the LDL receptor promoter blocked the induction of this
promoter reporter in response to Fbw7 siRNA (Figure 5D, lower
right panel).
Members of the SREBP family of transcription factors regu-
late cholesterol and lipid metabolism, and our data indicate
that inactivation of Fbw7 results in stabilization of transcription-
ally active SREBP1 and enhanced expression of SREBP target
genes. Thus, we speculated that inactivation of endogenous
Fbw7 should enhance lipid synthesis. To test this hypothesis,
U2OS cells were treated with control or Fbw7 siRNA, and the
synthesis of cholesterol and fatty acids was monitored in the
transfected cells. In agreement with our hypothesis, the syn-
thesis of both cholesterol and fatty acids was enhanced up to
3-fold in cells treated with the Fbw7 siRNA (Figure 5E). Taken
together, these results suggest that endogenous Fbw7 nega-
tively regulates the stability of nuclear SREBP, thereby regulat-
ing the expression of SREBP target genes and lipid synthesis.
Stabilization of nuclear SREBP in Fbw7−/− cells
Fbw7-deficient mice have been generated, and these animals
die in utero at embryonic day 10.5 as a result of impaired vas-
cular development. Attempts to isolate mouse embryonic fibro-
blasts from such immature embryos have not been successful.
However, Fbw7-deficient HCT116 colon carcinoma cells have
been generated (Rajagopalan et al., 2004). The steady-state
levels of nuclear SREBP1 were increased in the Fbw7−/−
HCT116 cells when compared to the parental cells, whereas
the levels of the precursor form of SREBP1 were unaffected
(Figure 6A). In agreement with our earlier observations, the
levels of nuclear SREBP2 were also enhanced in Fbw7−/− cells.
Semiquantitative RT-PCR analysis revealed that the expression
of the LDL receptor and HMG-CoA synthase genes, both of
which are positively regulated by SREBP, were increased sig-
nificantly in Fbw7−/− cells (Figure 6B), suggesting that stabiliza-
tion of nuclear SREBP results in enhanced expression of en-
dogenous target genes. In order to analyze the contribution of
individual Fbw7 isoforms to the turnover of SREBP1, Fbw7−/−
cells were transduced with retroviruses expressing either
Fbw7α, -β, or -γ, followed by selection of clones expressing
similar levels of the individual Fbw7 isoforms (Figure S7). Ex-
pression of nuclear Fbw7α and -γ in Fbw7−/− cells prevented
the accumulation of nuclear SREBP1, whereas the cytoplasmic
β isoform had no effect (Figure 6C). Interestingly, the same re-
sult was obtained when the abundance of cyclin E was ana-
lyzed (Figure 6C, middle panel). These data are in agreement
with our earlier results (Figures 1F and 1G) and indicate that
the α and γ isoforms of Fbw7 targets nuclear SREBP1 for deg-
radation, whereas Fbw7β is unable to do so. This hypothesis
was strengthened when the expression of endogenous SREBP
target genes was analyzed in the different Fbw7 clones by
semiquantitative RT-PCR. Expression of Fbw7α and -γ in
Fbw7−/− cells decreased the expression of SREBP target
genes, whereas the expression of Fbw7β had only a limited
effect (Figure 6D).386Fbw7 negatively regulates lipid synthesis
and metabolism
In agreement with our hypothesis, the synthesis of both cho-
lesterol and fatty acids was enhanced dramatically (8- to 10-
fold) in Fbw7−/− cells (Figure 7A). However, SREBPs do not only
regulate lipid synthesis but also lipid metabolism, since activa-
tion of the SREBP pathway results in enhanced expression of
the LDL receptor gene and, thereby, increased clearance of
LDL cholesterol from the circulation. Our earlier data demon-
strated that the expression of the LDL receptor gene was en-
hanced in Fbw7−/− cells. In agreement with these observations,
we found that the amount of LDL receptor protein was en-
hanced in Fbw7−/− cells (Figure 7B). To confirm that this activa-
tion translated into functional LDL receptor protein, we per-
formed LDL uptake assays in Fbw7+/+ and Fbw7−/− cells, using
fluorescently labeled LDL. The amount of fluorescent dye that
accumulates in lysosomes reflects the cell surface LDL recep-
tor activity. There was a remarkable increase in the intensity of
intracellular fluorescence in Fbw7−/− cells when compared with
Fbw7+/+ cells (Figure 7C), indicating a substantial increase in
LDL receptor activity in a majority of the Fbw7−/− cells. The
liver plays an important role in the regulation of whole-body
lipid metabolism, and Fbw7α is expressed in most human tis-
sues, including liver. To determine if Fbw7 could affect SREBP
function and lipid metabolism in liver cells, we used siRNA to
suppress endogenous Fbw7 in HepG2 cells. Mature SREBP1
and -2 accumulated in HepG2 cells treated with Fbw7 siRNA
(Figure 7D). Consequently, the expression of the SREBP-
dependent HMG-CoA synthase and LDL receptor promoter re-
porter genes were enhanced in response to Fbw7 inactivation
(Figure 7E). Inactivation of Fbw7 in HepG2 cells also resulted
in a 3-fold induction of cholesterol synthesis (data not shown)
as well as an increase in the levels of LDL receptor protein
(Figure 7D). Importantly, receptor-mediated uptake of LDL in
HepG2 cells was enhanced in response to inactivation of Fbw7
(Figure 7F), suggesting that Fbw7 regulates SREBP function
and lipid metabolism also in liver cells.
In summary, our data demonstrate that Fbw7 negatively reg-
ulates the stability and function of nuclear SREBP1 and -2 by
promoting their ubiquitination and proteasome-mediated deg-
radation through a phosphorylation-dependent mechanism.
Consequently, Fbw7 regulates the expression of SREBP target
genes and, thereby, the synthesis of cholesterol and fatty
acids, as well as receptor-mediated uptake of LDL. In addition,
our results suggest that these processes are regulated by insu-
lin signaling.
Discussion
Members of the SREBP family of transcription factors control
lipid synthesis and metabolism. The transcriptionally active
forms of these proteins are rapidly degraded by the ubiquitin-
proteasome pathway. We now demonstrate that nuclear
SREBP1 and -2 are degraded by an Fbw7-dependent pathway.
Fbw7 had previously been found to promote the degradation
of cyclin E and c-Myc after phosphorylation within their CPD
motifs. We demonstrate that the nuclear forms of SREBP1
and -2 are targeted for degradation by Fbw7 subsequent to
phosphorylation within domains that are highly related to the
CPD motifs found in cyclin E and c-Myc. We identify two resi-
dues in nuclear SREBP1a, T426 and S430, that are phosphory-CELL METABOLISM : JUNE 2005
Phosphorylation-dependent ubiquitination of SREBPFigure 6. Stabilization of nuclear SREBP in Fbw7−/−
cells
A) Total cell lysates were prepared from Fbw7+/+
and Fbw7−/− HCT116 cells and analyzed by SDS-
PAGE. The levels of SREBP1, SREBP2, and Cul1 in
cell lysates were detected by Western blotting. The
migration of the precursor (FL) and nuclear (N) forms
of SREBP1 is indicated.
B) RNA was isolated from Fbw7+/+ and Fbw7−/−
cells, and the abundance of transcripts derived from
the indicated genes was determined by RT-PCR.
C) Total cell lysates were prepared from Fbw7+/+
(lane 1) and Fbw7−/− (lane 2) cells or from Fbw7−/−
cells reconstituted with the indicated Fbw7 isoforms
(lanes 3–5). The levels of nuclear SREBP1, cyclin E,
and Cul1 in cell lysates were detected by Western
blotting.
D) RNA was isolated from Fbw7+/+ (lane 1) and
Fbw7−/− (lane 2) cells or from Fbw7−/− cells reconsti-
tuted with the indicated Fbw7 isoforms (lanes 3–5).
Total RNA was used to determine the expression of
the low-density lipoprotein receptor (LDLr, left
panel) and 3-hydroxy-3-methylglutaryl coenzyme A
synthase (HMG-CoA, right panel) genes by semi-
quantitative RT-PCR. The level of GAPDH mRNA in
each sample was used for normalization. The re-
sults are presented as fold induction over the mRNA
levels found in Fbw7+/+ cells. The results represent
the average ±SD of one representative experiment
performed in triplicate.lated by GSK-3, both in vitro and in vivo. Mutation of either of
these residues blocked the interaction between nuclear
SREBP1a and Fbw7 and inhibited Fbw7-mediated degradation
of SREBP1a. In addition, inactivation of endogenous GSK-3
reduced the phosphorylation of both T426 and S430 and atten-
uated Fbw7-mediated degradation of nuclear SREBP1a. The
precursor form of SREBP1 was not phosphorylated on T426
or S430 and was not sensitive to Fbw7-dependent degrada-
tion. Our results are in agreement with the recent observation
that SREBP1c (also known as ADD1) is phosphorylated by
GSK-3, both in vitro and in vivo (Kim et al., 2004). Although the
authors did not identify the phosphorylated residues, it was
demonstrated that GSK-3 inhibited SREBP-dependent tran-
scription. The SREBP1a and SREBP1c proteins originate from
a single gene as a result of alternative splicing and use of alter-
native promoters, and the two proteins only differ in the length
of the amino terminal transactivation domain (Osborne, 2000).
Thus, the sequence surrounding T426 and S430 is identical in
both proteins. We have found that SREBP1c is phosphorylated
on residues corresponding to T426 and S430 and that
SREBP1c is degraded in response to Fbw7 expression (Figures
S1 and S2 and data not shown). Thus, Fbw7-mediated degra-
dation of SREBP1c could, at least in part, explain the negative
effect of GSK-3 on the transcriptional activity of SREBP1c. InCELL METABOLISM : JUNE 2005support of this hypothesis, we found that the phosphorylation
of T426 and S430 was decreased and that nuclear SREBP1
accumulated when GSK-3 was inhibited in response to insulin
signaling. Thus, our results suggest that inactivation of GSK-3
in response to insulin signaling attenuates the phosphorylation
of the CPD motif in SREBP1, thereby blocking Fbw7-mediated
degradation of nuclear SREBP1. However, it is also possible
that GSK-3 phosphorylates other residues in SREBP1 and that
these modifications have effects on the transcriptional and/or
DNA binding activities of SREBP1. Mutation of the residues
corresponding to T426 and S430 in SREBP2, S432 and S436,
blocked the interaction between SREBP2 and Fbw7 as well as
Fbw7-mediated degradation of SREBP2, suggesting that
phosphorylation of these residues is critical for Fbw7-mediated
degradation of SREBP2.
The stability and function of SREBP1 were negatively af-
fected in response to Fbw7 expression, and Fbw7-mediated
degradation of SREBP1 was impaired by mutation of the Fbw7
F box or by pharmacological inhibition of proteasome function.
The membrane-associated precursor form of SREBP1 was not
phosphorylated on T426 or S430, and Fbw7 did not affect the
degradation of this form of the protein, indicating that Fbw7-
mediated degradation is specific for the nuclear form of
SREBP1. The role of endogenous Fbw7 in the degradation of387
A R T I C L EFigure 7. Fbw7 negatively regulates lipid synthesis and metabolism
A) Fbw7+/+ (lane 1) and Fbw7−/− (lane 2) cells were placed in fresh media supplemented with [14C]acetate for 2 hr. Fatty acids (upper) and cholesterol (lower) were
extracted and resolved by thin-layer chromatography. Radioactive products were visualized by phosphoimage analysis.
B) Total cell lysates were prepared from Fbw7+/+ (lane 1) and Fbw7−/− (lane 2) cells. The levels of LDL receptor and α-tubulin were detected by Western blotting.
C) Fbw7+/+ (left) and Fbw7−/− (right) cells were placed in fresh media supplemented with fluorescently labeled LDL (Dil-LDL) for 4 hr. The cells were washed, fixated,
and examined by fluorescence microscopy. Photographs were taken using identical exposure times and camera settings.
D) HepG2 cells were transfected with control or Fbw7 siRNA (20 nM) for 48 hr. The expression of SREBP1, SREBP2, LDL receptor, and α-tubulin were determined by
Western blotting. The migration of the precursor (FL) and nuclear (N) forms of SREBP1 is indicated.
E) HepG2 cells were transfected with the indicated promoter reporter constructs in the presence of either control or Fbw7 siRNA (20 nM). Thirty-six hours after
transfection, the luciferase activity was measured.
F) HepG2 cells were transfected with control or Fbw7 siRNA (20 nM) for 48 hr. Receptor-mediated uptake of Dil-LDL was analyzed as described in (C).endogenous SREBP1 and -2 was studied by siRNA-mediated
silencing of Fbw7 as well as a parallel approach employing
Fbw7-deficient cells. Inhibition of Fbw7 by either approach en-
hanced the abundance of nuclear SREBP1 and -2 and en-
hanced the expression of SREBP target genes. Importantly, in-
hibition of Fbw7 resulted in enhanced synthesis of both
cholesterol and fatty acids, suggesting that Fbw7-mediated
degradation of nuclear SREBP is physiologically relevant. This
hypothesis was supported by our observation that receptor-
mediated uptake of LDL was enhanced in cells lacking Fbw7,
demonstrating that Fbw7 controls both lipid synthesis and me-
tabolism.
The human Fbw7 locus encodes three protein isoforms,
Fbw7α, Fbw7β, and Fbw7γ (Jin et al., 2004). By reconstitution
of Fbw7-deficient cells with the individual Fbw7 proteins, we
have demonstrated that expression of Fbw7α and Fbw7γ re-388versed both the accumulation of nuclear SREBP1 and the acti-
vation of SREBP target genes seen in Fbw7−/− cells, whereas
Fbw7β was inactive. We also found a similar isoform specificity
following coexpression of nuclear SREBP1a and the three dif-
ferent Fbw7 proteins. Both Fbw7α and Fbw7γ are nuclear,
whereas Fbw7β is localized to the cytoplasm, supporting our
observation that Fbw7-mediated degradation of SREBPs is re-
stricted to the nuclear forms of the proteins.
The fbw7 gene is found within a chromosomal region that is
mutated in many human cancers, and Fbw7 mutations have
been found in cancer cells. The fact that SREBPs, c-Myc, and
cyclin E are all Fbw7 substrates could reflect coordinate regu-
lation of these proteins in normal cells. In addition, SREBP1,
cyclin E, and c-Myc are phosphorylated by GSK-3 within their
CPD motifs, and all proteins become resistant to Fbw7-driven
turnover when GSK-3 is inhibited. Thus, SREBPs could shareCELL METABOLISM : JUNE 2005
Phosphorylation-dependent ubiquitination of SREBPelements within the signal transduction and proteolytic path-
ways with key regulators of cell growth and division. Members
of the SREBP family of transcription factors regulate lipid syn-
thesis, and the synthesis of membrane lipids is critical for cell
growth and proliferation. Thus, loss of Fbw7 in cancers may
deregulate membrane lipid synthesis, thereby promoting cell
growth. It will, therefore, be important to analyze the phosphor-
ylation of T426/S430 and the interaction between SREBP1 and
Fbw7 in response to extracellular signals known to regulate cell
growth and proliferation. We hope that the phosphorylation-
specific anti-SREBP1 antibodies described in the current study
will be helpful in these efforts. We have demonstrated that
GSK-3 phosphorylates both T426 and S430 in vitro and in vivo
and that inhibition of endogenous GSK-3 attenuates Fbw7-
mediated degradation of SREBP1. However, it is possible that
other kinases will also phosphorylate T426 and/or S430, de-
pending on the cell type and extracellular signal. A more
extensive analysis of the kinases targeting the CPD motifs in
SREBPs is, therefore, warranted. In conclusion, our results de-
monstrate that Fbw7 controls the stability and function of all
members of the SREBP family of proteins by inducing their
phosphorylation-dependent ubiquitination. Cardiovascular dis-
ease is highly correlated with elevated levels of cholesterol in
the circulation. The most common treatment for elevated cho-
lesterol levels in humans is a group of drugs called statins.
These compounds block cholesterol synthesis and, therefore,
activate SREBPs. Activation of SREBPs results in enhanced
expression of the LDL receptor gene and, thereby, increased
clearance of LDL cholesterol from the circulation (Brown and
Goldstein, 1999). We have demonstrated that inactivation of
Fbw7 enhances the expression of SREBP target genes, includ-
ing the LDL receptor gene, and that this results in enhanced
synthesis of cholesterol and fatty acids as well as enhanced
receptor-mediated uptake of LDL. Thus, the phosphorylation
of the CPD motifs in SREBP1 and -2 and their interaction with
Fbw7 may be attractive targets when developing new choles-
terol-lowering therapies.
Experimental procedures
Cell culture
All tissue culture media and antibiotics were obtained from Invitrogen and
Sigma. HEK293T, HEK293, HepG2, U2OS, and HeLa cells were from ATCC.
Fbw7+/+ and Fbw7−/− HCT116 cells were provided by B. Vogelstein (Rajago-
palan et al., 2004) and were used at a low passage number.
Reagents and antibodies
Anti-Flag antibody (M5), cycloheximide, and standard chemicals were from
Sigma. Monoclonal anti-Myc (9E10), anti-SREBP1 (E4 and 2A4), anti-tubulin
(TU-02), anti-GST (B-14), anti-cyclin E (C-19), anti-LDL receptor (C7), goat
anti-SREBP2 (N-19), and rabbit anti-SREBP1 (H-160) antibodies were from
Santa Cruz. Anti-Cul1 antibody was from Zymed. Anti-GSK-3β was from
Cell Signaling, and recombinant GSK-3β was from NEB.
Generation of phosphorylation-specific SREBP1 antibodies
Synthetic phosphopeptides corresponding to residues 423–429 (T426
phosphorylated) and 427–433 (S430 phosphorylated) in human SREBP1a
were coupled to keyhole limpet haemocyanin before being injected into
rabbits. The phosphopeptides and the corresponding nonphosphorylated
peptides, as well as phospho-Ser (anti-pS430) and phospho-Thr (anti-
pT426), were coupled to Sulpholink (Pierce) and used as affinity matrixes
to purify the individual antibodies from rabbit sera.CELL METABOLISM : JUNE 2005Plasmids, retroviruses, DNA transfections, and viral infection
The expression vectors for Flag- and Myc-tagged SREBP1a, SREBP1c, and
SREBP2 (amino acid residues 2–490, 2–466, and 2–485, respectively) have
been described (Sundqvist and Ericsson, 2003). Point mutants in SREBP1a
and SREBP2 were generated by site-directed mutagenesis (QuickChange,
Stratagene). The HMG-CoA synthase (SYNSRE-luc), farnesyldiphosphate
synthase (FPPS-luc), and LDL receptor (LDLr-luc and LDLrSRE-luc) pro-
moter reporter constructs have been described (Dooley et al., 1998; Erics-
son et al., 1996; Sanchez et al., 1995). All other expression vectors have
been described previously (Koepp et al., 2001; Welcker et al., 2004). Tran-
sient transfections were performed using the MBS transfection kit (Strata-
gene). The Fbw7 (Fbw7.2), GSK-3β, and control siRNA were from Ambion
and have been described (Welcker et al., 2004; Welcker et al., 2003). MSCV-
based retroviruses expressing various Fbw7 isoforms were generated using
Gateway cloning vectors (Invitrogen). pMSCV-Fbw7α, β, and γ or empty
vector was transfected into retrovirus packaging cells (Phoenix) using
calcium phosphate-based transfection procedures. Two days after trans-
fection, viruses were harvested and used to infect HCT116 cells lacking
Fbw7 as indicated. Cells were selected with puromycin (1 g/ml) for 2
weeks. Individual colonies were picked and analyzed by RT-PCR to detect
Fbw7 expression.
Immunoprecipitations and immunoblotting
Cells were lysed in buffer A (50 mM HEPES [pH 7.2], 150 mM NaCl, 1 mM
EDTA, 20 mM NaF, 2 mM sodium orthovanadate, 10 mM β-glycerophos-
phate, 1% (w/v) Triton X-100, 10% (w/v) glycerol, 1 mM PMSF, 10 mM
sodium butyrate, 1% aprotinin, 0.1% SDS, and 0.5% sodium deoxycholate)
and cleared by centrifugation. For coimmunoprecipitations, cell lysates
were prepared in the absence of SDS and sodium deoxycholate. For ubiqui-
tination assays, cell lysates were prepared under denaturing conditions and
processed as described (Sundqvist and Ericsson, 2003). Cell lysates and
immunoprecipitates were resolved by SDS-PAGE and transferred to nitro-
cellulose membranes (Millipore). To ensure that equal amounts of protein
were loaded in each well, the levels of α-tubulin or Cul1 in the samples
were estimated by Western blotting. Proteins were in vitro translated using
the T7 TNT kit (Promega) and 35S-labeled methionine and cysteine and in-
cubated with 6xHis-SREBP1a followed by immunoprecipitation of SREBP1a.
The samples were washed extensively and resolved by SDS-PAGE.
Determination of protein half-life
Cells were treated with cycloheximide to stop protein synthesis and incu-
bated for the indicated times. Total cell lysates were prepared and the pro-
teins separated by SDS-PAGE and transferred to nitrocellulose membranes.
SREBP1 was visualized by Western blotting followed by quantitation on a
CCD camera (Fuji) and image analysis software (Aida Image Analyzer 3.10).
Peptide pull-down assays
Four separate peptides corresponding to residues 422–433 of human
SREBP1a or the same peptide phosphorylated on T426, S430, or both resi-
dues were synthesized using Fmoc chemistry. The peptides were coupled
to Sulpholink and used in peptide pull-down assays with cell lysates from
293T cells expressing Flag-Fbw7α in buffer A. The immobilized peptides
were washed three times in buffer A, and the bound proteins were sub-
jected to SDS/PAGE and Western blotting using 20% of input as controls.
Luciferase and β-galactosidase assays
Cells were transiently transfected with the indicated promoter reporter
genes in the absence or presence of expression vectors for SREBP1a,
either wild-type or the indicated mutants. Where indicated, the media was
supplemented with cholesterol and 25-hydroxycholesterol (50 and 5.0 g/
ml, respectively) to suppress the activation of endogenous SREBPs. After
36 hr, luciferase activities were determined in duplicate samples as de-
scribed by the manufacturer (Promega). The pCH110 vector encoding the
β-galactosidase gene under the control of the SV40 promoter (Amersham
Biosciences) was used as an internal control for transfection efficiency. Lu-
ciferase values (relative light units [RLU]) were calculated by dividing the
luciferase activity by the β-galactosidase activity. The data represent the
average ±SD of three independent experiments performed in duplicates.389
A R T I C L EAnalysis of lipid synthesis
Cells were placed in fresh media supplemented with [14C]acetate (10 Ci/
ml) and incubated for 2 hr. The cells were washed, trypsinized, and col-
lected by centrifugation. The pelleted cells were hydrolyzed in 60% (w/v)
KOH in methanol, and the nonpolar lipids (cholesterol) were extracted in
hexane. Following addition of 1 M HCl, polar lipids (fatty acids) were ex-
tracted in chloroform:methanol (2:1). The lipids were resolved by thin-layer
chromatography (Silica gel 60, Merck). The radioactive products were iden-
tified by comparison with unlabeled standards, visualized with iodine vapor.
LDL uptake assays
Cells grown on coverslips were incubated with fluorescently labeled LDL
(Dil-LDL) for 4 hr, washed, and fixed in 2% paraformaldehyde in PBS for 20
min at room temperature. The cells were subsequently permeabilized in
0.2% Triton X-100 in PBS, washed in PBS, and incubated in 10 mM glycine
in PBS. Nuclei were stained with DAPI. Intracellular fluorescent dye was
detected by microscopy using Axioplan-2 Zeiss (Jena, Germany) rhodamine
filters with a Hamamatsu ORCA CCD digital camera and identical exposure
times and camera settings.
RT-PCR assays
RNA was extracted with Trizol reagent (Invitrogen). mRNA was subjected to
RT with oligo dT, followed by PCR with target-specific primers. The PCR
reactions, using Invitrogen High-Fidelity DNA polymerase, were optimized
for the individual target genes. The PCR programs and primer sequences
for the human LDL receptor, HMG-CoA synthase, Fbw7α, Fbw7β, Fbw7γ,
SREBP1, β-actin, and GAPDH genes are available on request.
Supplemental Data
Supplemental Data include seven figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/1/6/379/DC1/.
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